PCRX - Pacira BioSciences, Inc.

https://www.pacira.com

Hold Momentum: Bearish

Recent News

Neutral

Is the Options Market Predicting a Spike in Pacira BioSciences Stock?

Zacks Commentary • 2 months, 4 weeks ago • score: 0.14

Investors need to pay close attention to PCRX stock based on the movements in the options market lately.

Neutral

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

Zacks Commentary • 4 months ago • score: 0.11

PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.

52W High

$27.64

52W Low

$12.61

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.42

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

7.92

EV/EBITDA (<8 favorable)

48.00

EV/Revenue (<3 favorable)

1.95

P/S (TTM) (<3 favorable)

1.68

P/B (<3 favorable)

1.57

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.82%

Institutions (25–75% balanced)

115.91%

Shares Outstanding

44,932,700

Float

39,826,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

705,848,000

Gross Profit (TTM)

469,429,000

EPS (TTM)

-2.75

Profit Margin (>10% good)

-0.18%

Operating Margin (TTM) (higher better)

0.05%

ROE (TTM) (>15% strong)

-0.16%

EPS YoY (Quarterly) (>10% good)

-0.48

Revenue YoY (Quarterly) (>8% good)

0.02

Momentum

Bearish momentum

Value

1.0262

1.0977

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025